Readystate Asset Management LP Purchases 303,958 Shares of Immunome, Inc. $IMNM

Readystate Asset Management LP increased its position in Immunome, Inc. (NASDAQ:IMNM) by 23.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,605,820 shares of the company’s stock after purchasing an additional 303,958 shares during the quarter. Immunome makes up about 1.2% of Readystate Asset Management LP’s investment portfolio, making the stock its 13th largest holding. Readystate Asset Management LP’s holdings in Immunome were worth $34,027,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC purchased a new stake in Immunome in the second quarter worth $552,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Immunome by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after buying an additional 1,625 shares during the period. Wellington Management Group LLP lifted its position in Immunome by 10.1% during the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after buying an additional 478,239 shares during the period. Capstone Investment Advisors LLC bought a new stake in shares of Immunome during the 2nd quarter valued at $299,000. Finally, Corient Private Wealth LP bought a new stake in shares of Immunome during the 2nd quarter valued at $916,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

NASDAQ IMNM opened at $26.76 on Monday. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $30.06. The stock has a market cap of $3.04 billion, a P/E ratio of -10.58 and a beta of 2.13. The stock’s fifty day moving average price is $24.96 and its 200-day moving average price is $22.58.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, analysts forecast that Immunome, Inc. will post -2.38 earnings per share for the current fiscal year.

Insider Activity at Immunome

In other Immunome news, Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the completion of the transaction, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. This represents a 77.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is owned by insiders.

Analysts Set New Price Targets

IMNM has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wedbush boosted their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Citigroup restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Leerink Partners lowered their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and an average target price of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.